IDEXX Laboratories (NASDAQ:IDXX) Director Sells 2,203 Shares

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Lawrence Kingsley sold 2,203 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

IDEXX Laboratories Trading Down 1.0%

NASDAQ:IDXX traded down $5.06 on Wednesday, reaching $515.15. The company’s stock had a trading volume of 554,634 shares, compared to its average volume of 578,740. IDEXX Laboratories, Inc. has a 12-month low of $511.16 and a 12-month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The firm has a market cap of $40.58 billion, a price-to-earnings ratio of 36.23, a price-to-earnings-growth ratio of 2.86 and a beta of 1.54. The stock has a 50 day moving average price of $558.13 and a 200 day moving average price of $568.61.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on IDXX. Citigroup increased their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Barclays decreased their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $747.00.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories during the second quarter worth about $25,000. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Elevation Wealth Partners LLC boosted its stake in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the period. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $26,000. Finally, WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.